Upadacitinib API powder

Xi'an Faithful BioTech Co., Ltd: Your Trusted Upadacitinib API powder Manufacturer & Supplier

Xi'an Faithful BioTech Co., Ltd is a leading supplier of high-quality Upadacitinib API powder. Our main products include pharmaceutical intermediates and active pharmaceutical ingredients. Since its establishment, the company has always adhered to the business philosophy of enhancing enterprise value and customer value as the core, and its mission is to serve society and care for others. Our products are exported to more than 20 countries around the world.

Upadacitinib API powder Introduction

Upadacitinib API powder is a JAK1 inhibitor that has shown good efficacy in clinical trials for the treatment of various autoimmune and inflammatory diseases. Used for treating diseases such as rheumatoid arthritis and psoriatic arthritis. Upadacitinib (ABT-494) has a selectivity for JAK1 that is approximately 74 times higher than JAK2 (200 nM). The appearance is white powder. We introduce advanced equipment, improve processes, and precisely control every step of the pharmaceutical process. Our Upadacitinib API powder has a purity of 99%. Can meet the needs of experimentation and production.

Specifications

 Why Choose Us?

The purity of the raw material is ≥ 99%, and key impurities (such as process impurities and degradation impurities) are controlled in accordance with international pharmacopoeia standards. Strict stability tests (accelerated test for 6 months, long-term test for 24 months) are conducted to ensure the stability of the raw materials during the production process of the formulation.
The factory optimizes the synthesis process (using green and environmentally friendly synthesis routes to reduce the generation of by-products), improves production efficiency, and provides market competitive prices while ensuring high quality, helping customers reduce the production cost of formulations;
Provide price locking mechanisms, priority supply rights, and other benefits for long-term cooperative customers.

Main applications

Upadacitinib API powder, as a highly selective JAK1 inhibitor, focuses on drug development and commercial production in the field of autoimmune disease treatment, including:
Used for the development of formulations (such as tablets, sustained-release formulations) for the treatment of rheumatoid arthritis, targeting moderate to severe active patients with insufficient response or intolerance to Methotrixate. By inhibiting the JAK1 signaling pathway, joint swelling, pain, and functional impairment are significantly improved;
Used for developing drugs to treat psoriatic arthritis, covering symptoms such as multi joint and attachment point inflammation in patients with active psoriatic arthritis, while also improving skin lesions;
Used to develop formulations for the treatment of atopic dermatitis (such as oral formulations), targeting patients with moderate to severe atopic dermatitis, relieving symptoms such as itching, erythema, and exudation, and improving their quality of life;
Expanding drug development for other autoimmune diseases such as ankylosing spondylitis and ulcerative colitis, with high selectivity of JAK1 targets, reducing the inhibitory effect on JAK2/JAK3, and reducing the risk of adverse reactions such as anemia and infection.

if you need it , you can click here

Quality Control:

R&D Results:

Packaging and Transportation:

After-Sales Service:

Qualification Certification:

Transaction Feedback:

Exhibition:

FAQ

Q1:What is the mechanism of Upadacitinib API powder?

A1:JAK Inhibitor: It's a selective inhibitor of Janus kinase (JAK) enzymes, specifically JAK1.

Blocks Inflammation: By blocking JAK1, it interrupts signaling pathways that activate immune cells and produce inflammatory cytokines, reducing inflammation.

Q2:Is upadacitinib an immunosuppressant?

A2:Upadacitinib is an immunosuppressant. This means that it reduces the activity of the immune system. Upadacitinib works by blocking the action of enzymes called Janus kinases, which are involved in processes that lead to inflammation.

Q3:Is upadacitinib safe long term?

A3:Acne was the most commonly reported AE at 76 weeks, which is similar to the results observed at weeks 16 and 52. Overall, upadacitinib is an efficacious JAK/STAT inhibitor that continues to demonstrate a consistent safety profile in long-term studies of patients with moderate to severe AD.

Contact Us

Are you intersted in Upadacitinib API powder?  pls feel free to contact us sales12@faithfulbio.com to get more information.